In this episode of "TOP CEO," host Ben Kaplan engages with Rahul Kakkar, CEO of Tome Biosciences, exploring the dramatic shifts in the biotech industry and how emerging companies navigate financial and technological hurdles. Founded in 2021, Tome Biosciences has been at the forefront of gene editing technology, thriving amidst substantial economic downturns that have challenged the sector. Rahul discusses strategic pivots and operational efficiencies that have allowed Tome to maintain innovation under financial constraints, delves into the high-risk, high-reward nature of biotech investments, and explains how changing interest rates and investment trends have shaped the industry landscape. Join us as Rahul shares insights from Tome's journey through optimistic beginnings and trials of fundraising during industry lows, revealing critical decisions that have set the stage for the company's future endeavors.